Authors
Latest:
Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast CancerKristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.
Latest:
Turning the Tide on Opioid Prescribing PracticesAs evidence grows that opioids may potentially worsen oncologic outcomes, surgeons and oncology providers must take an active role in addressing the opioid crisis by adopting similar protocols that decrease the quantity of narcotics available for diversion while ensuring safe patient care.
Latest:
Dr. Bosse on Immunotherapy in Pediatric CancersKristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the use of immunotherapy in the treatment of pediatric patients with cancer.
Latest:
TILs Show Growing Potential as Novel ImmunotherapyAlthough checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.
Latest:
The Great Biomarker Chase: Promise & Pitfalls Along the Path to Personalized CareBiomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.
Latest:
The Year's New Drugs: Integrating Advances of 2011 Into Treatment PlansThe FDA approved more new oncology drugs in 2011 than it has in a single year in more than a decade, thanks in part to priority review and streamlined evaluation procedures. While this is good news for patients, oncology and hematology specialists must tackle the challenges posed by integrating new therapies into treatment plans. Leading specialists give their perspectives on key issues.
Latest:
Dr. Sankhala on Challenges Facing the Treatment of AngiosarcomaKumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.
Latest:
Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy StrategyRoswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.
Latest:
Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast CancerBreast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.
Latest:
Dr. Tauer on Arguments in Favor of and Against Biosimilars in OncologyKurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.
Latest:
Practice Benchmark Report Offers Hope for Survival of Independent Oncology PracticesThe narrowing difference between operating cost and total medical revenue has eased, buying some time for practices to adjust their business models and perhaps survive.
Latest:
Dr. Tauer on the Expansion of Subtyping in Breast CancerKurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.
Latest:
Dr. Wong on the Current Landscape of NSCLCKwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).
Latest:
Dr. Richards on Unanswered Questions in Treating Bladder CancerKyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.
Latest:
Dr Agrawal on First-Line Treatment Approaches in HER2+ Breast CancerLaila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.
Latest:
Dr. Pusztai on the Promise of ctDNA Assays in Breast CancerLajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.
Latest:
Dr. Pusztai on Challenges With Neoadjuvant HER2 TherapyLajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer
Latest:
Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast CancerLajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.
Latest:
Dr. Rajdev on the Efficacy of Pembrolizumab/Chemotherapy in Esophageal CancerLakshmi Rajdev, discusses the efficacy of pembrolizumab (Keytruda) plus chemotherapy in patients with esophageal cancer.
Latest:
Digital Health and Process Improvements Enhance Community-Based Patient CareA marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.
Latest:
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) ExpressionDr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer and high folate receptor-alpha expression.
Latest:
Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney CancerLana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.
Latest:
Dr. Kandalaft on an Ovarian Cancer ImmunotherapyLana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.
Latest:
Reduce Costs By Using Less RadiotherapyRadiation therapy remains fertile for continued technological innovation that can improve patient outcomes, but of the newest technologies may be practical for only the largest institutions.
Latest:
Methods on Improving Survivorship and Palliative CareLani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.
Latest:
Dr. Kujtan on Frontline Therapy for EGFR-Positive NSCLCLara Kujtan, MD, assistant professor at the University of Missouri–Kansas City School of Medicine, discusses frontline therapy for patients with EGFR-positive non–small cell lung cancer (NSCLC).
Latest:
Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple MyelomaLarry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.
Latest:
Dr. Copeland on the Importance of Germline Testing in Ovarian CancerLarry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.
